Continuous infusion of 5-fluorouracil plus low-dose cisplatin in tumor-bearing mice

Anti-Cancer Drugs

Volumn 8, Issue 6, 1997, Pages 632-636

  Kamano, Toshiki ^a   Mikami, Yoshi ^a   Shirasaka, Tetsuhiko ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b Osaka Setsuro Fujii Mem Found P   (Japan)

Author keywords

Tetrahydrofolate; Thymidylase synthase; Treated:control ratio of tumor weights; White blood cells

Indexed keywords

CISPLATIN; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INFUSION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SARCOMA 180;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; INFUSIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME;

EID: 0030823271     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199707000-00012     Document Type: Article

References (14)

1. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923-5.
2. Shirasaka T, Shimamoto Y, Ohshimo H, Kimura A, Fukushima M. Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil. Jpn J Cancer Chemother 1991; 18: 403-9.
3. Shirasaka T, Shimamoto Y. Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167-72.
4. Loehrer PJ Sr, Einhorn LH, Williams SD, Hui SL, Estes NC Pennington K. Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon. Cancer Treat Rep 1985; 69: 1359-63.
5. Bernal AG, Cruz JJ, Sanchez P, et al. Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer. Cancer 1989; 63: 1927-30.
6. Jeske J, Hansen RM, Libnoch JA, Anderson T. 5-fluorouracil infusion and low-dose weekly cisplatin: an analysis of increased toxicity. Am J Clin Oncol 1990; 13: 485-8.
7. Cantrell JE Jr, Hart RD, Taylor RF, Harvey JH Jr. Pilot trial of prolonged continuous infusion of 5-fluorouracil and weekly cisplatin in advanced colorectal cancer. Cancer Treat Rep 1987; 71: 615-8.
8. Chung YS, Yumashita Y, Nakata B, et al. Combination therapy of 5-FU and low-dose CDDP for advanced and recurrent gastric cancer. Jpn J Cancer Chemother 1995; 22: 149-51.
9. Murase M, Kondo K, Kodera Y, et al. The clinical effect of chemotherapy with 5-FU and low-dose CDDP in patients with advanced gastric cancer. Jpn J Cancer Chemother 1994; 21: 1025-8.
10. Satoh Y, Une Y, Fujisawa J, et al. Effect of continuous infusion of 5-fluorouracil and daily low-dose cisplatin for inoperable recurrent cancer of the stomach and colon. Jpn J Cancer Chemother 1995; 22: 87-92.
11. Yamashita Y, Chung YS, Kato Y, et al. Combination therapy of low-dose (continuous) 5-FU and low-dose (daily) CDDP for advanced and recurrent digestive cancer. J Jpn Soc Cancer Ther 1994; 29: 1297 (abstr).
12. Stewart CF, Fleming RA. Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection. Am J Hosp Pharm 1990; 47: 1373-7.
13. Ishiyama S, Sakabe T, Ushio S, et al. 5-Fluorouracil as an antineoplastic agent. Jpn J Cancer Clin 1967; 13: 139-50.
14. Rosenberg B, van Camp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature 1969; 222: 285-6.